Stay updated on LowDose IL-2 & Pembrolizumab in Melanoma/RCC Clinical Trial

Sign up to get notified when there's something new on the LowDose IL-2 & Pembrolizumab in Melanoma/RCC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the LowDose IL-2 & Pembrolizumab in Melanoma/RCC Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The page now presents the ClinicalTrials.gov record for a withdrawn study of low-dose interleukin-2 and pembrolizumab for melanoma and renal cell cancer, including its study design and participant criteria.
    Difference
    54%
    Check dated 2026-11-09T13:09:22.000Z thumbnail image
  2. Check
    13 days ago
    Change Detected
    Summary
    The site footer revision identifier changed from v3.7.2 to v3.8.0, while the page continues to display a 403 Forbidden message.
    Difference
    0.2%
    Check dated 2026-11-02T12:41:51.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    A site-wide notice announces an NIH website transition and says that some NIH content may use “Super Intelligence” in place of “Artificial Intelligence.”
    Difference
    1%
    Check dated 2026-10-26T14:14:41.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    The footer’s displayed site revision changed from v3.7.1 to v3.7.2; the study page remains a 403 error page.
    Difference
    0.2%
    Check dated 2026-10-19T14:07:01.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    The site footer revision changes from v3.7.0 to v3.7.1; the page still displays a 403 Forbidden error instead of the study record.
    Difference
    0.2%
    Check dated 2026-10-12T14:41:49.000Z thumbnail image
  6. Check
    54 days ago
    Change Detected
    Summary
    The study record now displays a 403 Forbidden page, blocking access to the study details and related sections.
    Difference
    19%
    Check dated 2026-09-21T20:24:04.000Z thumbnail image

Stay in the know with updates to LowDose IL-2 & Pembrolizumab in Melanoma/RCC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the LowDose IL-2 & Pembrolizumab in Melanoma/RCC Clinical Trial page.